Hemp, Inc. Reports: Marijuana-Cannabidiol (CBD) Bill Signals New Era in Federal Cannabis Policy

Contributing sentiments towards policy:

64% : It's a new dawn, a new day as the first bill solely related to marijuana is sent to POTUS after being approved by the U.S. House and Senate - an unfathomable feat a decade ago.
60% : Yes, there is evidence suggesting marijuana is beneficial in treating glaucoma and epilepsy.
59% : Additionally, the bill directs the DEA to register manufacturers and distributors of CBD or marijuana for the purpose of commercial production of an approved drug that contains marijuana or its derivative.
59% : Finally, the bill includes various other provisions, including provisions that:· require the DEA to assess whether there is an adequate and uninterrupted supply of marijuana for research purposes;· prohibit the Department of Health and Human Services (HHS) from reinstating the interdisciplinary review process for marijuana research;· allow physicians to discuss the potential harms and benefits of marijuana and its derivatives (including CBD) with patients; and· require HHS, in coordination with the National Institutes of Health and relevant federal agencies, to report on the therapeutic potential of marijuana for various conditions such as epilepsy, as well as the impact on adolescent brains and on the ability to operate a motor vehicle.
55% : Specifically, the bill directs the Drug Enforcement Administration (DEA) to follow specified procedures to register (1) practitioners to conduct marijuana research, and (2) manufacturers to supply marijuana for the research.
55% : It's the first legislation to unite opponents and proponents of cannabis legalization.
54% : The bill allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research.
52% : Per Congress.gov, the Medical Marijuana and Cannabidiol (CBD) Research Expansion Act will:Establish a new, separate registration process to facilitate research on marijuana.
51% : After years of championing legislation to legalize marijuana for medical purposes, the H.R. 8454 - Medical Marijuana and Cannabidiol (CBD) Research Expansion Act marks a "historic breakthrough in addressing the federal government's failed and misguided prohibition of cannabis."
47% : Passed by unanimous consent, by the Senate, the marijuana-related bill signals times are changing and so are perceptions about marijuana.
40% : These are just a couple of questions researchers have not been able to answer because marijuana is a Schedule 1 controlled substance with bureaucratic hurdles and security measures deterring "would-be researchers" from finding the answers.
38% : According to an article in Cardinal News, opponents want evidence that marijuana is harmful and proponents want evidence that it's useful for medical applications.
33% : Too many lives have been upended because of our failed approach to marijuana.

*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.